These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36515253)
1. Utility of the ACC/AHA Lesion Classification to Predict Outcomes After Contemporary DES Treatment: Individual Patient Data Pooled Analysis From 7 Randomized Trials. Konigstein M; Redfors B; Zhang Z; Kotinkaduwa LN; Mintz GS; Smits PC; Serruys PW; von Birgelen C; Madhavan MV; Golomb M; Ben-Yehuda O; Mehran R; Leon MB; Stone GW J Am Heart Assoc; 2022 Dec; 11(24):e025275. PubMed ID: 36515253 [TBL] [Abstract][Full Text] [Related]
2. [Evaluating the long-term prognosis of coronary artery disease patients undergoing percutaneous coronary intervention by risk stratification with ACC/AHA classification of coronary lesions]. Qiu MH; Zhao WC; Fan P; Bian LY; Li J; Li Y; Han YL Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Feb; 48(2):111-117. PubMed ID: 32135610 [No Abstract] [Full Text] [Related]
3. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859 [TBL] [Abstract][Full Text] [Related]
4. Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. Guedeney P; Claessen BE; Mehran R; Mintz GS; Liu M; Sorrentino S; Giustino G; Farhan S; Leon MB; Serruys PW; Smits PC; von Birgelen C; Ali ZA; Généreux P; Redfors B; Madhavan MV; Ben-Yehuda O; Stone GW JACC Cardiovasc Interv; 2020 Jun; 13(12):1417-1428. PubMed ID: 32553329 [TBL] [Abstract][Full Text] [Related]
5. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. Chandrasekhar J; Baber U; Sartori S; Stefanini GG; Sarin M; Vogel B; Farhan S; Camenzind E; Leon MB; Stone GW; Serruys PW; Wijns W; Steg PG; Weisz G; Chieffo A; Kastrati A; Windecker S; Morice MC; Smits PC; von Birgelen C; Mikhail GW; Itchhaporia D; Mehta L; Kim HS; Valgimigli M; Jeger RV; Kimura T; Galatius S; Kandzari D; Dangas G; Mehran R JACC Cardiovasc Interv; 2018 Jan; 11(1):53-65. PubMed ID: 29301648 [TBL] [Abstract][Full Text] [Related]
6. Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents. Hemetsberger R; Abdelghani M; Toelg R; Mankerious N; Allali A; Garcia-Garcia HM; Windecker S; Lefèvre T; Saito S; Slagboom T; Kandzari D; Koolen J; Waksman R; Richardt G J Am Heart Assoc; 2021 Jun; 10(12):e019815. PubMed ID: 34056911 [TBL] [Abstract][Full Text] [Related]
7. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661 [TBL] [Abstract][Full Text] [Related]
8. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial. Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S; JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. Giustino G; Baber U; Aquino M; Sartori S; Stone GW; Leon MB; Genereux P; Dangas GD; Chandrasekhar J; Kimura T; Salianski O; Stefanini GG; Steg PG; Windecker S; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari DE; Galatius S; Von Birgelen C; Saporito R; Jeger RV; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R JACC Cardiovasc Interv; 2016 Apr; 9(7):674-84. PubMed ID: 27056305 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis. Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ; JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063 [TBL] [Abstract][Full Text] [Related]
11. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202 [TBL] [Abstract][Full Text] [Related]
13. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts. Lee JM; Hahn JY; Kang J; Park KW; Chun WJ; Rha SW; Yu CW; Jeong JO; Jeong MH; Yoon JH; Jang Y; Tahk SJ; Gwon HC; Koo BK; Kim HS JACC Cardiovasc Interv; 2015 Aug; 8(10):1318-1331. PubMed ID: 26315734 [TBL] [Abstract][Full Text] [Related]
14. Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials. Hemetsberger R; Abdelghani M; Toelg R; Garcia-Garcia HM; Farhan S; Mankerious N; Elbasha K; Allali A; Windecker S; Lefèvre T; Saito S; Kandzari D; Waksman R; Richardt G Clin Res Cardiol; 2022 Jul; 111(7):795-805. PubMed ID: 35212802 [TBL] [Abstract][Full Text] [Related]
15. Long term outcomes of ultrathin versus standard thickness second-generation drug eluting stents: Meta-analysis of randomized trials. Hussain Y; Gaston S; Kluger J; Shah T; Yang Y; Tirziu D; Lansky A Catheter Cardiovasc Interv; 2022 Feb; 99(3):563-574. PubMed ID: 34236755 [TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients. Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615 [TBL] [Abstract][Full Text] [Related]
17. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial. Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057 [TBL] [Abstract][Full Text] [Related]
18. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. Kedhi E; Généreux P; Palmerini T; McAndrew TC; Parise H; Mehran R; Dangas GD; Stone GW J Am Coll Cardiol; 2014 May; 63(20):2111-2118. PubMed ID: 24632279 [TBL] [Abstract][Full Text] [Related]
19. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [TBL] [Abstract][Full Text] [Related]
20. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Konigstein M; Smits PC; Love MP; Ben-Yehuda O; Ozan MO; Liu M; Perlman GY; Leon MB; Stone GW; Kandzari DE JACC Cardiovasc Interv; 2020 Jan; 13(1):86-93. PubMed ID: 31918946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]